KCNN4 and Parkinson disease: Using the same KCa3.1 blocker in mice models, which were injected with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a Parkinson’s-inducing neurotoxin, improved the locomotion, attenuated microgliosis and neuroinflammation in the substantia nigra pars compacta and reduced dopaminergic (DA) neuronal loss [48].